Table 2.
Concentration that induces 50% growth inhibition of cells compared with untreated cells (IC50) (μM) of the [Ru(apy)(tpy)L2 n−](2−n)+ complexes (1a, 1b, 1c) and their dinuclear analogue [Ru(apy)(tpy)]2[μ-H2N(CH2)6NH2](ClO4)4 (1f) after a 5-day treatment with selected cell lines
| Compound tested | A498 | EVSA-T | H226 | IGROV | M19 MEL | MCF7 | WIDR |
|---|---|---|---|---|---|---|---|
| [Ru(apy)(tpy)Cl](ClO4) (1a) | >96 | 7 | 17 | >96 | 25 | 13 | 66 |
| [Ru(apy)(tpy)(H2O)](ClO4)2·2H2O (1b) | >81 | 6 | 17 | 44 | 26 | 18 | 50 |
| [Ru(apy)(tpy)(CH3CN)] (ClO4)2 (1c) | >82 | 6 | 26 | 78 | 30 | 21 | 73 |
| [Ru(azpy)(tpy)Cl]Cl·5H2O (1d) | 39 | 11 | 34 | 65 | 15 | 30 | 51 |
| [Ru(apy)(tpy)]2[μ-H2 N(CH2)6NH2] (ClO4)4 (1f) | >40 | 17 | 28 | >40 | 33 | >40 | >40 |
| α-[Ru(azpy)2Cl2] | 0.3 | 0.1 | 0.5 | 0.3 | 0.1 | 0.3 | 0.3 |
| Cisplatin | 2 | 1 | 2 | 0.2 | 3 | 2 | 2 |
α-[Ru(azpy)2Cl2] and cisplatin have been included as reference compounds